Fremanezumab

Generic Name: Fremanezumab

Brand Names: Ajovy

Drug Type: Biotech

CAS Number: 1655501-53-3

Unique Ingredient Identifier: PF8K38CG54

Background: Fremanezumab is a humanized monoclonal antibody targeted against human calcitonin gene-related peptide (CGRP) for the prevention of migraine headaches. It was developed by Teva Pharmaceuticals USA and approved by the FDA in September 2018. Along with other recently approved anti-CGRP therapies such as galcanezumab, erenumab, and the oral CGRP antagonist ubrogepant, fremanezumab represents an important step forward in the treatment and prevention of migraine headaches.

Indication: Fremanezumab is indicated for the preventative treatment of migraine in adults.

Associated Conditions: Migraine

Clinical Trials

Fremanezumab for the Prevention of Menstrually-related Migraine Attacks

Recruiting

Conditions: Menstrual Migraine

Interventions: Drug: Fremanezumab

First Posted Date: 2024-10-26

Last Posted Date: 2024-10-26

Lead Sponsor: Insel Gruppe AG, University Hospital Bern

Target Recruit Count: 120

Registration Number: NCT06659120

Locations: 🇨🇭
Department of Neurology, Inselspital, Bern, Switzerland

The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab

Phase 4

Recruiting

Conditions: Migraine Without Aura
Brain Diseases
Migraine Disorders
Migraine With Aura

Interventions: Drug: Fremanezumab Prefilled Syringe

First Posted Date: 2024-02-06

Last Posted Date: 2024-02-06

Lead Sponsor: Hospital Clínico Universitario de Valladolid

Target Recruit Count: 87

Registration Number: NCT06244823

Locations: 🇪🇸
Hospital Clínico Universitario de Valladolid, Valladolid, Spain

Migraine Medication Effects on Urinary Symptoms

Conditions: Bladder Pain Syndrome
Migraine Disorders
Migraine
Overactive Bladder
Overactive Bladder Syndrome
Overactive Detrusor
Interstitial Cystitis

Interventions: Drug: Ubrogepant
Drug: Botulinum toxin A
Drug: Rimegepant
Drug: Atogepant
Drug: Eptinezumab
Drug: Fremanezumab
Drug: Galcanezumab
Drug: Erenumab

First Posted Date: 2024-01-19

Last Posted Date: 2024-05-16

Lead Sponsor: The Cleveland Clinic

Target Recruit Count: 200

Registration Number: NCT06212661

Locations: 🇺🇸
Cleveland Clinic, Main Campus, Cleveland, Ohio, United States

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

Phase 4

Recruiting

Conditions: Migraine
Menstrual Migraine
Menstrually Related Migraine

Interventions: Drug: Fremanezumab
Other: Placebo

First Posted Date: 2023-12-18

Last Posted Date: 2024-05-16

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 72

Registration Number: NCT06173661

Locations: 🇺🇸
Brigham and Women's Health Care Center, Chestnut Hill, Massachusetts, United States

A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine

Phase 3

Completed

Conditions: Migraine

Interventions: Drug: Fremanezumab
Drug: Placebo

First Posted Date: 2022-07-14

Last Posted Date: 2025-01-31

Lead Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.

Target Recruit Count: 365

Registration Number: NCT05458011

Locations: 🇨🇳
Teva Investigational Site 88022, Changsha Shi, China
🇨🇳
Teva Investigational Site 88015, Suzhou Shi, China
🇨🇳
Teva Investigational Site 88023, Tianjin Shi, China

and more 26 locations

Specified Drug Use Survey on AJOVY Subcutaneous Injection for Long-term Use

Recruiting

Conditions: Migraine Disorders

Interventions: Drug: Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution

First Posted Date: 2022-04-22

Last Posted Date: 2025-03-21

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 1000

Registration Number: NCT05342493

Locations: 🇯🇵
Pharmacovigilance Department, Osaka, Japan

Real World Effectiveness of Eptinezumab in Participants With Migraine

Phase 4

Terminated

Conditions: Migraine

Interventions: Drug: Eptinezumab
Drug: Onabotulinumtoxin-A
Drug: Erenumab
Drug: Fremanezumab
Drug: Galcanezumab

First Posted Date: 2022-03-17

Last Posted Date: 2024-05-29

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 32

Registration Number: NCT05284019

Locations: 🇺🇸
Gilbert Neurology Partners/ CCT Research, Gilbert, Arizona, United States
🇺🇸
Ki Clinical Research LLC, dba New England Institute for Clinical Research, Stamford, Connecticut, United States
🇺🇸
Innovation Medical Group, Palmetto Bay, Florida, United States

and more 7 locations

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

Recruiting

Conditions: Migraine
Migraine With Aura
Migraine Without Aura
Chronic Migraine
Episodic Migraine

Interventions: Drug: Erenumab
Drug: Galcanezumab
Drug: Fremanezumab

First Posted Date: 2022-03-16

Last Posted Date: 2022-10-20

Lead Sponsor: Austrian Migraine Registry Collaboration

Target Recruit Count: 1500

Registration Number: NCT05281770

Locations: 🇦🇹
Medical University Innsbruck, Innsbruck, Tirol, Austria
🇦🇹
Clinic Hietzing, Vienna, Austria
🇦🇹
Medizinische Universität Wien, Wien, Vienna, Austria